Michael Yu

1.7k total citations
59 papers, 1.0k citations indexed

About

Michael Yu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Michael Yu has authored 59 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 24 papers in Oncology and 14 papers in Genetics. Recurrent topics in Michael Yu's work include Brain Metastases and Treatment (19 papers), Glioma Diagnosis and Treatment (14 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Michael Yu is often cited by papers focused on Brain Metastases and Treatment (19 papers), Glioma Diagnosis and Treatment (14 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Michael Yu collaborates with scholars based in United States, Canada and Spain. Michael Yu's co-authors include Weg M. Ongkeko, Selena Z. Kuo, Jessica Wang‐Rodriguez, Alan Kiang, Arnold B. Etame, Solmaz Sahebjam, Peter A.S. Johnstone, Kamran A. Ahmed, Eric Y. Chang and Jaideep Chakladar and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Michael Yu

51 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Yu United States 16 455 324 302 180 146 59 1.0k
Zhan Feng China 22 530 1.2× 284 0.9× 243 0.8× 388 2.2× 71 0.5× 60 1.3k
George Chen United States 16 303 0.7× 188 0.6× 335 1.1× 87 0.5× 44 0.3× 35 906
Bernardo Cacho‐Díaz Mexico 12 203 0.4× 236 0.7× 141 0.5× 47 0.3× 150 1.0× 67 705
Chao Ma China 21 369 0.8× 173 0.5× 205 0.7× 552 3.1× 108 0.7× 120 1.3k
Lara R. Heij Netherlands 19 429 0.9× 261 0.8× 178 0.6× 190 1.1× 24 0.2× 63 1.2k
Ekokobe Fonkem United States 17 180 0.4× 179 0.6× 381 1.3× 67 0.4× 359 2.5× 71 1.2k
Andrea Balogh Hungary 20 220 0.5× 163 0.5× 778 2.6× 264 1.5× 42 0.3× 36 1.3k
Andrea Remo Italy 26 754 1.7× 299 0.9× 586 1.9× 133 0.7× 57 0.4× 76 1.7k
Feng‐Ming Hsu Taiwan 21 283 0.6× 428 1.3× 343 1.1× 166 0.9× 61 0.4× 79 1.1k
Boel Brynedal Sweden 17 326 0.7× 150 0.5× 290 1.0× 92 0.5× 37 0.3× 34 1.4k

Countries citing papers authored by Michael Yu

Since Specialization
Citations

This map shows the geographic impact of Michael Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Yu more than expected).

Fields of papers citing papers by Michael Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Yu. The network helps show where Michael Yu may publish in the future.

Co-authorship network of co-authors of Michael Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Yu. A scholar is included among the top collaborators of Michael Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Yu. Michael Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Michael, C. Christina Mehta, Jessica A. Alvarez, et al.. (2025). Noninvasive Markers of Hepatic Steatosis and Fibrosis Following Integrase Strand-Transfer Inhibitor Initiation in Women With HIV. Clinical Infectious Diseases. 81(2). 304–313.
2.
Gray, Daniel T., et al.. (2025). Dynamic changes in mitochondria support phenotypic flexibility of microglia. Nature Communications. 16(1). 11103–11103.
3.
4.
Piña, Yolanda, Vincent Law, Solmaz Sahebjam, et al.. (2025). Phase IB study of Avelumab and whole brain radiotherapy in patients with leptomeningeal disease from solid tumors: Results and molecular analyses. Neuro-Oncology. 27(12). 3237–3249.
5.
Liu, Yan, Ye Chen, R. Yu, et al.. (2024). A Phase II Clinical Trial of Sintilimab Combined with Lower Dose Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 120(2). e433–e434. 1 indexed citations
6.
Ahmed, Kamran A., Youngchul Kim, Daniel Oliver, et al.. (2024). Phase I/II study of stereotactic radiation and sacituzumab govitecan with zimberelimab in the management of metastatic triple negative breast cancer with brain metastases.. Journal of Clinical Oncology. 42(16_suppl). TPS1140–TPS1140.
7.
8.
9.
Weiss, Matthew J., Shane English, Frédérick D’Aragon, et al.. (2020). Survey of Canadian critical care physicians’ knowledge and attitudes towards legislative aspects of the deceased organ donation system. Canadian Journal of Anesthesia/Journal canadien d anesthésie. 67(10). 1349–1358. 7 indexed citations
10.
Li, Wei Tse, Jiayan Ma, Jaideep Chakladar, et al.. (2020). Using machine learning of clinical data to diagnose COVID-19: a systematic review and meta-analysis. BMC Medical Informatics and Decision Making. 20(1). 247–247. 122 indexed citations
11.
Ahmed, Kamran A., Sungjune Kim, John A. Arrington, et al.. (2017). Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. Journal of Neuro-Oncology. 133(2). 331–338. 99 indexed citations
12.
Ahmed, Kamran A., Y.A. Abuodeh, Michelle Echevarria, et al.. (2016). Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Annals of Oncology. 27(12). 2288–2294. 107 indexed citations
13.
Yu, Michael, Alan Kiang, Jessica Wang‐Rodriguez, et al.. (2012). Nicotine Promotes Acquisition of Stem Cell and Epithelial-to-Mesenchymal Properties in Head and Neck Squamous Cell Carcinoma. PLoS ONE. 7(12). e51967–e51967. 46 indexed citations
14.
Fourkal, E, Mu‐Han Lin, C Ma, et al.. (2012). WE‐A‐BRB‐06: 3D In‐Patient Dose Reconstruction from the PET‐CT Imaging of Y‐90 Microspheres for Metastatic Cancer to the Liver. Medical Physics. 39(6Part25). 3932–3932. 1 indexed citations
15.
Smaldone, Marc C., David Y. Chen, Robert G. Uzzo, & Michael Yu. (2011). Molecular imaging of the small renal mass. Urologic Oncology Seminars and Original Investigations. 29(6). 589–592. 2 indexed citations
16.
Altuna, Xabier, Jay Patrick Lopez, Michael Yu, et al.. (2010). Potential Role of Imatinib Mesylate (Gleevec, STI-571) in the Treatment of Vestibular Schwannoma. Otology & Neurotology. 32(1). 163–170. 18 indexed citations
17.
Blair, Katherine J., Alan Kiang, Jessica Wang‐Rodriguez, et al.. (2010). EGF and bFGF Promote Invasion That Is Modulated by PI3/Akt Kinase and Erk in Vestibular Schwannoma. Otology & Neurotology. 32(2). 308–314. 34 indexed citations
18.
Husain, Zain, Navesh Sharma, Alexandra L. Hanlon, et al.. (2010). Low Pretreatment PET SUV Predicts for Increased Local Failure following Stereotactic Body Radiation Therapy for Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 78(3). S525–S525. 3 indexed citations
19.
Thompson, Paul M., George Bartzokis, Kôji Hayashi, et al.. (2008). Time-Lapse Mapping of Cortical Changes in Schizophrenia with Different Treatments. Cerebral Cortex. 19(5). 1107–1123. 83 indexed citations
20.
Lopez, Jay Patrick, Jessica Wang‐Rodriguez, Michael Yu, et al.. (2008). Gefitinib (Iressa) Potentiates the Effect of Ionizing Radiation in Thyroid Cancer Cell Lines. The Laryngoscope. 118(8). 1372–1376. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhan Feng Breakdown of academic impact, for papers by George Chen Breakdown of academic impact, for papers by Bernardo Cacho‐Díaz Breakdown of academic impact, for papers by Chao Ma Breakdown of academic impact, for papers by Lara R. Heij Breakdown of academic impact, for papers by Ekokobe Fonkem Breakdown of academic impact, for papers by Andrea Balogh Breakdown of academic impact, for papers by Andrea Remo Breakdown of academic impact, for papers by Feng‐Ming Hsu Breakdown of academic impact, for papers by Boel Brynedal
Rankless by CCL
2026